Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting

4Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Introduction: Studies on treatment adherence to glucose-lowering drugs among patients with type 2 diabetes (T2D) including concomitant treatment for other cardiovascular risk factors are scarce. We aimed to estimate the prevalence of good adherence to all medications used to control diabetes, hypertension and dyslipidemia and to analyse cardiometabolic control and its associated factors in T2D patients in the primary care (PC) setting. Methods: Observational, retrospective study conducted in adult patients with T2D who were followed in the PC setting in Spain. Patients were classified as adherent in a particular category if the summary of the proportion of days covered (PDC) for a particular medication category was ≥80% and were considered globally adherent if the PDC was ≥80% for each of the 3 medication categories. Results: A total of 457 evaluable patients were recruited, among which 321 patients (70.3%, 95% CI 65.8 to 74.4) were adherent to the three drug categories. The proportion of patients controlled for the 3 cardiometabolic risk factors was 31% according to the contemporary clinical practice guideline criteria, 58% according to investigator judgment and 36% when the objective for HbA1c was individualized. In a multivariate analysis, presenting comorbidities was associated with a lower likelihood of showing adequate control of dyslipidemia (odds ratio [OR] 0.25, 95% CI, 0.16–0.40) and the three cardiometabolic factors as a whole (OR 0.43, 95% CI 0.26–0.70). In a post hoc analysis, therapeutic inertia was found to be greater for dyslipidemia and hypertension than for T2D. Conclusions: Despite a relatively high adherence to all medications for treating diabetes, hypertension and dyslipidemia in patients with T2D in the PC setting in Spain, the control of cardiometabolic risk factors as a whole is far from optimal. This could be related, at least in part, to the high frequency of comorbidity of these patients.

References Powered by Scopus

Adherence to medication

6778Citations
N/AReaders
Get full text

2016 European Guidelines on cardiovascular disease prevention in clinical practice

5692Citations
N/AReaders
Get full text

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

4058Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cardiovascular preventive recommendations. PAPPS 2022 thematic updates. Working groups of the PAPPS

13Citations
N/AReaders
Get full text

Cardiovascular preventive recommendations. PAPPS 2024 thematic updates

2Citations
N/AReaders
Get full text

Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Orozco-Beltrán, D., Cinza-Sanjurjo, S., Escribano-Serrano, J., López-Simarro, F., Fernández, G., Gómez García, A., … Cedenilla Horcajuelo, M. (2022). Adherence, control of cardiometabolic factors and therapeutic inertia in patients with type 2 diabetes in the primary care setting. Endocrinology, Diabetes and Metabolism, 5(2). https://doi.org/10.1002/edm2.320

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

53%

Researcher 5

26%

Professor / Associate Prof. 2

11%

Lecturer / Post doc 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

48%

Nursing and Health Professions 7

30%

Pharmacology, Toxicology and Pharmaceut... 4

17%

Biochemistry, Genetics and Molecular Bi... 1

4%

Save time finding and organizing research with Mendeley

Sign up for free